FSC/CytoSPAR, a bio-molecular engineering and diagnostic testing company, is currently developing and commercializing the proprietary Surface Programmable Activation Receptor (SPAR™) diagnostic and therapeutic platform. SPAR™ is a functional diagnostic platform, including a testing device and test cartridges that are preloaded with the company’s patented, universal, programmable biosensor. The biosensor is engineered for high sensitivity, specificity, stability, and speed-to-results for a number of bacteria and viruses. The device is small, rugged and portable with built-in quality controls, sample tracking, wireless communications, and can be easily operated by non-laboratory personnel.
SPAR™ Saves Time
When It Matters Most
While current detection systems require lengthy testing, with samples often being sent to remote facilities and taking days to get results, SPAR™ has no enrichment step. Modeled after the human body’s adaptive immune system, SPAR™ is designed to work fast “when it matters most” and smartly adapt to different environments and sample types as needed.
Twenty-five years of executive and entrepreneurial experience in both the business and legal arena. Russell has worked for Wal-Mart and Blockbuster as a Corporate Operations Turnaround Specialist and was able to make profits from money-losing divisions in less than 12 months. He has been involved with several startup operations, including an IPO and an exit.
Forty-four years in the design and marketing of medical devices. Past work experience includes Abbott Laboratories, Thermo Fischer Scientific, Inc., and Owens-Illinois. Charles has developed a range of patented, 510(k)-cleared products, including a portable clinical chemistry analyzer with disposable ISE sensors, an automated Osmometer, a diode array Hematocrit reader, an automated miniature centrifuge, and a micro ISE sensor.
Strategic Advisory Board
Dr. Eisenberg is Diagnostics Chief Scientific Officer and Sr. Vice President at LabCorp. She oversees Research and Development, Science and Technology, which includes test development, optimization and automation as well as Licensing and Business Development. She assists in the review of new tests, technologies and platforms and works with partners to transform their IP into viable diagnostic assays.
James (Jim) W. Hawkins, MBA, PhD, a FOCUS Managing Director, is also CEO of Metaphor Biopharmaceuticals, LLC. Dr. Hawkins has been President and CEO of numerous early stage biotechnology companies and has experience in all major areas of the biopharmaceutical industry including: drug discovery, diagnostics, analytical instrumentation, and specialty reagents and chemicals.
George Hara founded DEFTA Partners in 1984 and serves as its Founder, Group Chairman, and Chief Executive Officer. He is also a Partner at Pond Venture Partners Ltd. Mr. Hara is known as a leading edge venture capitalist and visionary leader in information technology in Japan and the Pacific Rim region. He is responsible for helping portfolio companies build international business alliances that aim to generate substantial revenue growth.
Stephen Mendel is a Venture Partner at Alsop Louie Partners. Among many c-level appointments, he has served as managing director and executive vice president of In-Q-Tel in charge of its venture capital activities, vice chairman of Knowledge Revolution (acquired by MSC Software), CEO and President of Ithaca Software (acquired by Autodesk), and executive vice president of Maxwell Communication Corporation (MCC).
Richard A. Moran, Ph.D., is a San Francisco based inspirational business leader, workplace pundit, bestselling author, venture capitalist and President Emeritus of Menlo College. Moran previously served as CEO and Vice Chairman at Accretive Solutions, Partner at Venrock, Chairman of the Board at Portal Software and as a Partner at Accenture.
Dennis Steadman is an executive leader with an uncommon record of success in large Fortune 100 corporations as well as entrepreneurial start-ups. He has been a senior executive with Merck and Merial animal health companies, leading both international and North American divisions. He was also Director and CEO of Velcera, Inc.; a company he led from concept to acquisition by a NYSE-listed multinational corporation.